BridgeBio Pharma, Inc. Common Stock (BBIO)
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering treatments for genetic diseases and cancers. Founded in 2015, the company aims to address underserved patient populations by advancing innovative therapies from research to commercialization.
Company News
BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis reduces cardiovascular outcomes in ATTR-CM patients, with significant risk reduction observed as early as the first month of treatment and sustained through 30 months.
Helix Acquisition Corp. II announced retaining approximately $120 million in its trust account, representing over 60% of cash, in connection with a business combination with BridgeBio Oncology Therapeutics. The transaction is expected to raise $382 million in gross proceeds, including $261 million from a private placement.
Pfizer discontinued development of an experimental weight-management pill, highlighting the risks of drug development. The company also faces upcoming patent expirations for key products and a potential slowdown in FDA approvals due to staffing changes at the agency.
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Forget about the Magnificent Seven and AI. The stocks that did the absolute best during the year were tied to biotech and crypto — along with one car-related company.